Bradken Resources Pty Ltd v Lynx Engineering Consultants Pty Ltd

Link copied
Case Copied 77 min read

FEDERAL COURT OF AUSTRALIA

Bradken Resources Pty Ltd v Lynx Engineering Consultants Pty Ltd [2012]
FCA
944

Citation: Bradken Resources Pty Ltd v Lynx Engineering Consultants Pty Ltd [2012] FCA 944
Parties: BRADKEN RESOURCES PTY LIMITED (ACN 098 300 988) v LYNX ENGINEERING CONSULTANTS PTY LIMITED (ACN 059 949 469)
File numbers: NSD 439 of 2007
WAD 212 of 2009
Judge: MCKERRACHER J
Date of judgment: 31 August 2012
Catchwords:

PATENTS – two appeals from decisions of delegate of Commissioner of Patents – opposition to grant of patent for bulk material transport container on multiple grounds – consideration of nature of appeals as hearings de novo

PATENTS – combination patent – novelty – whether invention was disclosed in prior art – application of ‘reverse infringement’ test – whether invention involved an inventive step – whether the combination of integers would have been an obvious solution to a person skilled in the art in light of common general knowledge – consideration of how a person skilled in the art would have interpreted and understood the prior art – time at which prior art is to be construed

PATENTS – disputed priority date – whether there was a ‘real and reasonably clear disclosure’ in the provisional specification – whether secret use before the priority date – whether use by inventor for reasonable trial and experiment only

EVIDENCE – consideration of admissibility and weight to be given to expert evidence where the expert witnesses are not independent

Legislation: Evidence Act 1995 (Cth) ss 76(1), 79, 80, 135(c)
Patents Act 1990 (Cth) ss 7, 9, 18, 40, 43, 59, 60
Patents Regulations 1991 (Cth) r 3.12(1)(b), r 5.9A, r 5.4
Cases cited:

Airsense Technology Ltd v Vision Systems Ltd (2007) 73 IPR 65

Aktiebolaget Hassle v Alphapharm Pty Ltd (2002) 212 CLR 411

Andrew Master Hones Ltd v Cruikshank and Fairweather [1981] 98 RPC 389
Apotex Pty Ltd v Sanofi-Aventis (2009) 82 IPR 416
Arrow Pharmaceuticals Ltd v Merck & Co Inc (2004) 63 IPR 85
Aspirating IP Ltd v Vision Systems Ltd (2010) 88 IPR 52
Austoft Industries Ltd v Cameco Industries Inc (No 2) (1995) 33 IPR 251
Azuko Pty Ltd v Old Digger Pty Ltd (2001) 52 IPR 75
Bradken Resources Pty Ltd v Lynx Engineering Consultants Pty Ltd (2010) 187 FCR 476
Bramah v Hardcastle (1789) 1 Carp Pat Cas 168
Britain v Hirsch [1888] 5 RPC 226
British Celanese Ltd v Courtaulds Ltd (1935) 52 RPC 171
Catnic Components Ltd v Hill & Smith Ltd [1982] 99 RPC 183
CCOM Pty Ltd v Jiejing Pty Ltd (1994) 51 FCR 260
Cincinnati Grinders Inc v BSA Tools Ltd [1931] 48 RPC 33
Costa v GR & IE Daking Pty Ltd (1994) 29 IPR 241
Dunlop Holdings Ltd's Application, Re [1979] 96 RPC 523

EI Dupont de Nemours & Co v Imperial Chemical Industries plc (2002) 54 IPR 304

F Hoffman-La Roche AG v New England Biolabs Inc (2000) 99 FCR 56
Flexible Steel Lacing Co v Beltreco Ltd (2000) 49…

CaseChat AU logo

Keep reading for free

Create a free CaseChat account to read Bradken Resources Pty Ltd v Lynx Engineering Consultants Pty... and more:

  • Read every judgment in full
  • Ask AI and get answers linked to paragraphs
  • See how each paragraph was cited in later cases
  • Download judgments as PDF or Word
Continue with Google

One click creates your free account or signs you in.

By continuing you agree to the Terms and Privacy Policy.

Details
Case
[2012] FCA 944
Decision Date

CaseChat Overview and Summary

Bradken Resources Pty Ltd has appealed against the decision of the Commissioner of Patents, allowing the grant of a patent to Lynx Engineering Consultants Pty Ltd for a bulk material transport container. The dispute involves the patentability of the container on grounds of novelty, inventive step, and secret use. The Federal Court of Australia heard two appeals from decisions of the Commissioner's delegate, which had allowed the patent application to proceed to grant.

The central legal issues the Court needed to decide included whether the invention disclosed in the patent application was novel and involved an inventive step. This involved applying the'reverse infringement' test to determine whether the invention would have been obvious to a person skilled in the art at the relevant time. The Court also had to consider the admissibility and weight of expert evidence provided by non-independent experts. Additionally, the Court examined whether there was a 'real and reasonably clear disclosure' in the provisional specification and whether there was secret use before the priority date.

The Court found that the invention was not novel as it was disclosed in prior art, and the combination of elements in the patent would have been an obvious solution to a person skilled in the art. The Court also found that the provisional specification did not provide a real and reasonably clear disclosure of the invention. Given these findings, the Court held that the patent was not valid on the grounds of novelty and inventive step. The Court further found that the evidence of secret use was not sufficient to invalidate the patent on that ground.

The Court ordered that the parties file submissions on the appropriate disposition of the appeals and cross-appeals, along with costs, within specified timeframes. The time for any further appeal would not commence until final orders were made.

Orders

Orders of the court

1. The respondent/cross-appellant file any submissions as to the appropriate disposition of the appeal/cross-appeal and costs within 21 days.

2. The applicant/cross-respondent file any submissions in response within a further 21 days.

3. The respondent/cross-appellant file any submissions in reply within 7 days.

4. Any further orders in relation to the matters the subject of orders 1, 2 and 3 be dealt with on the papers unless otherwise ordered.

5. The time for the institution of any appeal will not run until final orders disposing of the appeal/cross-appeal and costs are made.

Note: Entry of orders is dealt with in Rule 39.32 of the Federal Court Rules 2011.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

I have ruled on objections by means of category. Those rulings appear in Annexure C to these reasons.7.2 The competing expert evidence Bradken submits that Dr Mazur’s evidence going to the issue of inventive step must be totally or considerably discounted because of his intimate involvement in the Patent Application, his role as a director of Lynx, his involvement as an inventor and his ‘plain inability’ to dissociate himself as a senior executive of Lynx for the purpose of giving expert opinion evidence. Bradken argues that his evidence should be given little weight where it purports to contradict that of Mr Ivo Anic. In this regard Bradken relies on the following matters. First, both Dr Mazur and Mr Kris Kilian are the named inventors in respect of the Patent Application. They are both directors and shareholders of Lynx. They each have a clear interest in the outcome of the proceedings. Bradken contends that they both clearly lack the independence brought by Mr Anic to the task of assessing obviousness, as well as the other grounds of invalidity. They are also led as witnesses of fact – for example, in relation to Lynx’s defence of Bradken’s contentions in respect of ‘secret use’ relating to the prototype Golynx Wagons in 1998/1999. Secondly, Dr Mazur concedes that the starting point for his consideration of matters relating to validity, and the expression of his ‘expert’ opinions in relation to them, is that he has already formed the view that the Patent Application is valid. He acknowledges that he has held this view for some years, having previously expressed his views in evidence given by statutory declaration in the opposition proceedings. Thirdly, Bradken submits, many of Dr Mazur’s opinions are ‘infected’ by their failure to distinguish between the design for the Golynx Wagon (the embodiment of which is in fig 2a of the Patent Application) and the invention the subject of the claims. Fourthly, Dr Mazur’s written evidence in many respects differs ‘significantly’ from the oral evidence given during the course of cross-examination. This, it is said, is particularly apparent when one considers his strident written arguments put forward to defend the novelty attack on the basis of Gilpin, many of which ‘evaporated’ when his attention was drawn in detail to the wording of the claims of the Patent Application or Gilpin: see Dr Mazur’s first affidavit sworn on 23 December 2010 (at [173]-[174]) where he denies that geometric stiffening in the form of an internal ridge was well known at the priority date but resiled from this position in cross-examination. Bradken contends that Dr Mazur and Mr Kilian’s clear lack of independence is a significant matter which bears on the weight to be attributed to their opinions on inventive step, as well as the other grounds of invalidity: see The Wellcome Foundation Ltd v VR Laboratories Pty Ltd (1981) 148 CLR 262 (at 287); see also Termite Tite (NZ) No 2 Ltd v Term-Seal (Aust) Pty Ltd (2007) 74 IPR 16 per Besanko J (at [116]):As to the other point raised by the applicants, unless it is a particularly serious case of bias which might enliven the discretion to exclude, the fact that Dr Franklin is a party goes to the weight to be accorded to his evidence, not the admissibility of the evidence: J D Heydon, Cross on Evidence (7th Australian ed, 2004) (at [29080]) and cases cited therein; Ian Freckelton and Hugh Selby, Expert Evidence (3rd ed, 2005) (at 26 and 315-16) and cases cited therein.

Decision

Reasons for decision

After the First Decision, Lynx made amendments to the Original Application. Those amendments were also opposed but subsequently allowed by a Delegate (Amendment Decision). The Patent Application reverted to the Delegate for determination of whether the application as amended (Amended Application) overcame relevant grounds of objection to the claims (Second Decision). The second appeal (Federal Court proceeding WAD 212 of 2009) (Second Appeal) concerns the Delegate’s decision dated 13 November 2009 to allow the Patent Application as amended to proceed to grant. Bradken has at all times since the Amendment Decision contended that it is only the claims of the Amended Application (Amended Claims) which are relevant and properly before the Court. This is because the effect of the Delegate’s allowance of the amendment in the Amendment Decision is that ‘the amendment is taken to have been made’: s 104(6). The claims of the Original Application (Original Claims) no longer form part of the application. This point was raised before the Court by notice of motion, but not required to be determined in Bradken No 1. At the commencement of this hearing, Lynx informed the Court that it did not pursue the grant of the Patent Application in the form of the Original Claims. The hearing was conducted on the basis that only the Amended Application (including the Amended Claims) was to be the subject of determination in this proceeding (subject, Bradken says, to its costs thrown away). At the commencement of the hearing, Bradken was granted leave to file a Further Amended Consolidated Points of Claim (FACPC). The FACPC substantially reduced certain issues. On 28 February 2012, Bradken was also granted leave to file its Second Further Amended Consolidated Points of Claim (SFACPC), which further narrowed the issues in this Appeal. The question of costs in relation to the filing of Bradken’s FACPC and SFACPC has been reserved, although I indicated that I was favourably disposed to Lynx’s contention that it should have its costs thrown away by reason of the amendment. Lynx has not formally pleaded in response to the SFACPC. However the final hearing was conducted on the basis that Lynx opposed the matters and contentions advanced in the SFACPC. Further, I required the parties to commit to a list of agreed issues from the pleadings, to which oral and written argument on the evidence and the law was to be based. Their assistance in doing so has been valuable. Written submissions were extensive. I have adopted substantial parts of them at times. I have identified the party advancing any significant submission without repeating such attribution on every occasion when material is uncontentious. 2. DICTIONARY For ease of reference, the following dictionary is provided for terms used throughout these reasons: As noted in the Introduction, Bradken now relies on the following grounds of opposition to the grant of the Amended Application:(a)lack of novelty;(b)lack of inventive step; and(c)secret use.

Ratio Decidendi

Legal Principle Established

Full text does not contain this section.